《新股消息》艾迪康控股(09860.HK)公開發售輕微超購 一手中籤率100%
中國三大獨立醫學實驗室(或ICL)服務提供商之一艾迪康控股(09860.HK)公布招股結果,每股發售價12.32元,香港公開發售部分錄得輕微超額認購0.06倍。每手500股計,一手中籤率100%。該股將於明日(30日)掛牌。聯席保薦人為摩根士丹利及富瑞。
公司上市引入5名基石投資者,包括邁瑞醫療(300760.SZ)旗下邁瑞全球、新產業(300832.SZ)旗下香港新產業、復星醫藥(02196.HK)旗下復星診斷、Timestar Elite及Corelink,共認購2,364.7萬股公司股份,佔全球發售完成後公司股本約3.27%。
此外,公司上市料淨集資約8,390萬元,當中約15%用於加強普檢及特檢能力;約25%用於通過開設新實驗室、新增合夥投資及開發新渠道拓展網絡;約25%用於與行業參與者形成戰略合作的業務開發活動以及戰略性及附加收購;約15%用於升級及擴大現有實驗室;約10%用於投資營運基礎設施,包括物流設施、人工智能技術及IT基礎設施;約10%用作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.